Oxurion company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

oxurion.com

Stage

Unattributed | Alive

Total Raised

$35M

Last Raised

$35M | 1 yr ago

Revenue

$0000 

About Oxurion

Oxurion is a biopharmaceutical company focused on the development of therapeutics for conditions related to the vascular system. The Company has used its in-house expertise and collaborations with academic institutions to build a strong pipeline of promising drug candidates in cardiovascular diseases, visual disorders, and cancer.

Oxurion Headquarter Location

Gaston Geenslaan 1

Leuven, B-3001,

Belgium

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Oxurion

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Oxurion is included in 3 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

D

Diabetes

1,750 items

Oxurion Patents

Oxurion has filed 24 patents.

The 3 most popular patent topics include:

  • Diseases of the eye and adnexa
  • G protein coupled receptors
  • Ophthalmology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/19/2019

7/7/2020

Clusters of differentiation, Diseases of the eye and adnexa, G protein coupled receptors, Transcription factors, Integrins

Grant

Application Date

8/19/2019

Grant Date

7/7/2020

Title

Related Topics

Clusters of differentiation, Diseases of the eye and adnexa, G protein coupled receptors, Transcription factors, Integrins

Status

Grant

Latest Oxurion News

Oxurion Announces Two Presentations at The Macula Society 45th Annual Meeting

Jun 13, 2022

Oxurion Announces Two Presentations at The Macula Society 45th Annual Meeting 06/13/2022 | 01:01pm EDT Message : *Required fields Leuven, BELGIUM, Boston, MA, US – JUNE 13, 2022 – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that two presentations were delivered at The Macula Society 45th Annual Meeting, June 8 -11, 2022 in Berlin, Germany. The Macula Society presentations are available under Conferences and Events within the Investors section of the Company’s website. TITLE: KALAHARI: Part A Results of the Phase 2 Study of THR-149, a Plasma Kallikrein Inhibitor, in Subjects with DME Responding Sub optimally to anti-VEGF Treatment PRESENTER: Shree K. Kurup, MD, Dept. of Ophthalmology, University Hospitals, Cleveland, OH SUMMARY: In the high dose group: A mean BCVA gain of 6.1 letters was seen at Month 3, with gains observed up to Month 6 as well as CST stabilization over the 6-month study period compared to Baseline No need for rescue treatment Post-hoc analysis, excluding 2 subjects with abnormalities on OCT, showed a mean gain in BCVA of 9.3 letters at Month 3, which was maintained up to Month 6 THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of diabetic macular edema (DME) patients showing suboptimal response to anti-VEGF therapy. Oxurion is evaluating THR-149 for the treatment of DME in Part B, the second part of its two-part Phase 2 KALAHARI trial. TITLE: THR-687, a Potent and Highly Selective RGD Integrin Inhibitor in Development for the Treatment of Diabetic Macular Edema PRESENTER: Francesco Bandello, Professor and Chairman of the Department of Ophthalmology, VitaSalute, Milan, Italy SUMMARY: Study population was representative of treatment naïve DME patients based on the CRC feedback on OCT at BL Mean BL BCVA and CST values were aligned with naïve DME studies for other compounds There was insufficient evidence of efficacy on the key endpoints (BCVA and CST) THR-687 is safe and well tolerated No rescue medication was administered to any of the subjects The ocular AEs are consistent with the progressive nature of DME, no toxic drug effects occurred THR-687 is a highly selective pan-RGD integrin antagonist that Oxurion had been developing as a first line therapy for DME patients. Recently released data from Part A, the first part of its two-part Phase 2 INTEGRAL trial showed THR-687 to be safe and well tolerated with no serious adverse events and none of the patients requiring rescue medication through Month 3, however, there was insufficient evidence of efficacy on the key endpoints (Best-Corrected Visual Acuity and Central Subfield Thickness). As a result, Oxurion has decided not to advance THR-687 to Part B of the INTEGRAL trial. About Oxurion Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com. For more information, please contact: Oxurion NV

Oxurion Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Oxurion Rank

  • Where is Oxurion's headquarters?

    Oxurion's headquarters is located at Gaston Geenslaan 1, Leuven.

  • What is Oxurion's latest funding round?

    Oxurion's latest funding round is Unattributed.

  • How much did Oxurion raise?

    Oxurion raised a total of $35M.

  • Who are the investors of Oxurion?

    Investors of Oxurion include Negma Group and Gimv.

  • Who are Oxurion's competitors?

    Competitors of Oxurion include Sierra Oncology, Oligomerix, Dare Bioscience, Aphios, Array Biopharma and 13 more.

You May Also Like

A
AM-Pharma

AM-Pharma is a biopharmaceutical company that focuses on the development of recombinant Alkaline Phosphatase for clinical use.

Oligomerix Logo
Oligomerix

Oligomerix is a biopharmaceutical company focused on development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers and their newly discovered proteolytic enzymatic activity. The Company was founded in 2006 and is located within the Audubon Biomedical Science and Technology Park at Columbia University Medical Center.

B
BrainCells

BrainCells is a biopharmaceutical company focused on the development of small molecule therapeutics for diseases of the central nervous system (CNS). The company's technology platform is based on research in the field of neurogenesis and recent discoveries linking neurogenesis to CNS disease states. BCI is using its neurogenesis technology platform to identify clinical-stage compounds, targets and compounds optimal for CNS indications. BCI is building a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes and other CNS disorders.

Cerecin Logo
Cerecin

Cerecin is a biopharmaceutical company with a drug for Alzheimer's in late-stage clinical testing. Cerecin's pipeline consists of therapeutic drugs and medical foods for neurodegenerative diseases such as Alzheimer's, Parkinson's, and Age-Associated Memory Impairment.

B
BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.

T
TargAnox

TargAnox offers therapeutics to treat diseases resulting from oxidative stress-induced protein aging

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.